Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab ; volume:14 ; number:1 ; day:4 ; month:10 ; year:2024 ; pages:1-13 ; date:12.2024
Scientific reports ; 14, Heft 1 (4.10.2024), 1-13, 12.2024

Creator
Gordeev, Aleksandr
Vaal, Andrei
Puchkova, Maria
Smirnova, Iana
Doronin, Aleksandr
Znobishcheva, Anna
Zhmudanova, Daria
Aleksandrov, Aleksei
Sukchev, Mikhail
Imyanitov, Evgeny
Solovyev, Valery
Iakovlev, Pavel
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-024-72118-3
URN
urn:nbn:de:101:1-2501242124361.364235982077
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Gordeev, Aleksandr
  • Vaal, Andrei
  • Puchkova, Maria
  • Smirnova, Iana
  • Doronin, Aleksandr
  • Znobishcheva, Anna
  • Zhmudanova, Daria
  • Aleksandrov, Aleksei
  • Sukchev, Mikhail
  • Imyanitov, Evgeny
  • Solovyev, Valery
  • Iakovlev, Pavel
  • SpringerLink (Online service)

Other Objects (12)

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma

Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report

Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Hochschulschrift

Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren

Pembrolizumab

Pembrolizumab

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Pembrolizumab for all

Pembrolizumab for all

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy

Retrospektive Untersuchung zur Häufigkeit von unerwünschten immunvermittelten Ereignissen unter Immuntherapie mit Nivolumab oder Pembrolizumab bei älteren und jüngeren Patient*innen

Retrospektive Untersuchung zur Häufigkeit von unerwünschten immunvermittelten Ereignissen unter Immuntherapie mit Nivolumab oder Pembrolizumab bei älteren und jüngeren Patient*innen

Pembrolizumab: The Nut Cracker

Pembrolizumab: The Nut Cracker

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative study

Related objects